Roche, Novartis move Xolair closer to FDA finish line for food allergies

On Tuesday, Roche revealed that the FDA has accepted its supplemental biologics license application (sBLA) on a priority review basis for Xolair to reduce accidental allergic food reactions, including anaphylaxis, in adults and children ages 1 year and older.